Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07308418

The Influence of Vibrotactile Stimulation on Self-selected Walking Speed in People With Parkinson's Disease

The study tests whether a smart shoe (NUSHU) that provides vibrotactile stimulation can improve walking speed in people with Parkinson's disease. Sixteen participants complete two short walking tests-with and without vibration-to compare gait speed, cadence, stride length, usability, and safety. It is a low-risk pilot study meant to generate first evidence for future research.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Magnes AG

Zurich, Canton of Zurich, 8005, Switzerland

Location status: Recruiting

Location contact

Romina Willi

CONTACT

[email protected]

0442234873

About this study

Study Overview

This monozentric, prospective within-subject crossover pilot study investigates whether vibrotactile stimulation provided by the NUSHU, a CE-certified smart shoe, can influence spatiotemporal gait parameters-primarily self-selected walking speed-in adults with Parkinson's disease (PD). Parkinson's disease is often associated with reduced gait speed, shorter strides, and altered cadence, all of which are clinically relevant because they correlate with morbidity, fall risk, and quality of life.

Rationale

Earlier research suggests that vibration can positively influence gait by modulating proprioception, but existing devices have been impractical or clinically cumbersome. The NUSHU integrates sensors and vibration modules into an everyday shoe, enabling precise, phase-specific stimulation during the swing phase. Since no previous PD studies have tested this device, the project seeks to assess feasibility, safety, and initial efficacy signals.

Participants

Sixteen adults with a confirmed Parkinson's diagnosis will be recruited from multiple Physiozentrum Zürich locations. Key inclusion requirements include stable medication, ability to walk ≥ 200 m without resting, and sufficient understanding of German. Exclusion criteria include neuropathy, atypical parkinsonism, major comorbid gait disorders, or cognitive impairment that may interfere with procedures.

Study Design and Procedures

Participants attend a single 45-minute session consisting of:

Informed consent and eligibility assessment

Instruction on NUSHU use

Two 2-minute walking tests (with and without vibration), in randomized order

A 15-minute washout between tests

Completion of the System-Usability-Scale (SUS) questionnaire

Continuous monitoring and documentation of safety events and perceived stability

The assessor is blinded regarding the stimulation condition to reduce bias.

Outcomes

Primary outcome:

Difference in self-selected gait speed between vibration vs. no-vibration conditions.

Secondary outcomes:

  • Cadence
  • Stride length
  • Usability (SUS-DE)
  • Safety observations and subjective stability ratings

Statistics As an exploratory pilot, the study is not powered for confirmatory conclusions. Paired statistical tests (t-test or Wilcoxon) will evaluate within-subject differences. Descriptive methods and Bonferroni-corrected secondary analyses will complement the primary evaluation.

Ethics & Risk Classified as Risk Category A, the study involves minimal risk, mainly the normal risk associated with walking. Strict inclusion criteria and supervised testing aim to reduce fall risk. Data will be pseudonymized and securely stored. Although participants receive no direct clinical benefit, the findings will support future research on technology-assisted mobility strategies for PD.

Purpose:

  • Overall, the study aims to understand:
  • The short-term effect of vibrotactile stimulation on gait
  • The feasibility, usability, and safety of NUSHU in a PD population
  • Whether larger, controlled trials are justified

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • A medically confirmed diagnosis of Parkinson's disease on the physiotherapy prescription.
  • Stable medication for at least four weeks (no change in dopaminergic therapy).
  • The ability to walk at least 200 metres without stopping.
  • Minimum age: 18 years
  • Sufficient knowledge of German to understand the study information and complete the questionnaires.
  • Written informed consent form

Exclusion criteria

  • Atypical or secondary Parkinsonism
  • Sensory disturbances in the feet (e.g. polyneuropathy).
  • Other neurological, orthopaedic or internal medical conditions that significantly affect walking
  • Cognitive impairments that interfere with understanding the study information or following instructions

Treatment and study plan

Vibrotactile feedback during walking

Device

NUSHU smart shoes give real time gait feedback during walking.

Primary outcomes

  1. Change in self-selected walking speed (m/s)

    Time frame: Once during 120 seconds

    Change in self-selected walking speed (m/s), measured over a 2-minute walking test with and without stimulation by the NUSHU. Walking speed is measured in m/s as a continuous metric variable, which is an objective and established way of measuring walking speed. The calculation is performed by dividing the total distance covered by the time in seconds (120 seconds).

  2. Change in self-selected gait speed

    Time frame: One visit of 45 minutes

Study contacts

Contact information is provided by the study sponsor or research team.

Romina Willi

CONTACT

[email protected]

+41442234873

Sponsors and collaborators

Lead sponsor

Magnes AG

Industry

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Dec 29, 2025
Registry last updated
Mar 2, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.